Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...

Johnson & Johnson is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from ...

Key Takeaways Johnson & Johnson's fourth quarter sales met estimates, while net income fell short.After adjusting for ...

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales ...

The director of the National Institutes of Health, Dr. Monica Bertagnolli, announced that she will step down Friday, 14 ...

After decades of a diversified healthcare business model, Johnson & Johnson has announced it plans to split off its consumer health division from its pharma and medical device operations.

Johnson & Johnson’s Kenvue is to be its specialist Consumer Health division, separate from the company’s pharma and medical device operations. Indeed, Kenvue will apparently be guided by the ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Becton, Dickinson and Co. (BD) is investing in its U.S. manufacturing network to add capacity for critical medical devices, ...